Management of Relapsed and Refractory ALL

Abstract

Management of relapsed and/or refractory (R/R) acute lymphoblastic leukemia (ALL) presents a challenge given the poor response to salvage chemotherapy historically and seldom durable responses. There is an urgent need for novel treatment strategies. Over the past several years, the novel immune-based therapies targeting several surface antigens, including CD19, CD20, and CD22 expressed on B-lymphoblasts have demonstrated encouraging results in R/R ALL. These therapies have changed the treatment paradigm. The optimal use of these agents remains to be determined. In this chapter, we will discuss the current treatment landscape for adult patients with R/R ALL.